Zai Lab Ltd (HK:9688)
:9688
Want to see HK:9688 full AI Analyst Report?
9688 Stock Chart & Stats
HK$18.27
-HK$0.02(-0.10%)
At close: 4:00 PM EST
HK$18.27
-HK$0.02(-0.10%)
Day’s Range― - ―
52-Week RangeHK$12.31 - HK$35.50
Previous CloseN/A
Volume1.30M
Average Volume (3M)10.12M
Market Cap
HK$17.16B
Enterprise ValueHK$1.57B
Total Cash (Recent Filing)HK$761.63M
Total Debt (Recent Filing)HK$232.00M
Price to Earnings (P/E)―
Beta1.05
Next Earnings
Aug 10, 2026EPS Estimate
-0.53Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.16
Shares Outstanding1,134,128,000
10 Day Avg. Volume10,854,931
30 Day Avg. Volume10,116,373
Financial Highlights & Ratios
PEG Ratio0.28
Price to Book (P/B)2.68
Price to Sales (P/S)4.17
P/FCF Ratio-12.07
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$27.93Price Target Upside52.88% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)-1.56
Revenue Forecast (FY)HK$3.61B
Bulls Say, Bears Say
Bulls Say
Strategic Collaborations & Pipeline ProgressPartnerships with Amgen and Boehringer Ingelheim plus AACR data on zoci represent durable de-risking and acceleration of development. Large-partner trials and credible clinical readouts increase probability of regulatory success and global commercialization potential over the next 2–6 months and beyond.
Commercial Regional Business And LaunchesA commercially profitable regional unit provides recurring cash flow to fund R&D and operations. The imminent KarXT China launch and potential NRDL listing are structural events that can materially expand patient access and sustain product revenue, underpinning longer-term commercialization capacity.
High Gross Margins And Improving Loss IntensityConsistently high gross margins suggest scalable product economics and favorable unit profitability if sales recover. The multi-year reduction in loss intensity signals improving operating discipline and a clearer path to sustainable margins once revenue stabilizes, supporting long-term financial resilience.
Bears Say
Persistent Negative Operating And Free Cash FlowChronic negative operating and free cash flow implies ongoing cash burn that will require financing or dilution to sustain operations. Over the next 2–6 months this constrains flexibility to fund trials, launches, or manufacturing scale-up and increases refinancing and execution risk.
Sharp TTM Revenue Contraction And Top-line VolatilityA severe trailing-twelve-month revenue decline indicates volatile commercialization performance and undermines operating leverage. Persistent top-line weakness complicates planning, reduces margin absorption, and heightens reliance on milestone payments or partnerships to fund near-term R&D and launches.
Rising Leverage And Negative Returns On EquityIncreased leverage with a shrinking equity base and deeply negative ROE signals that capital is being consumed rather than compounded. This structural weakness raises financing costs and limits strategic optionality, elevating the risk profile for sustaining development and commercial expansion over the medium term.
Zai Lab Ltd News
9688 FAQ
What was Zai Lab Ltd’s price range in the past 12 months?
Zai Lab Ltd lowest stock price was HK$12.31 and its highest was HK$35.50 in the past 12 months.
What is Zai Lab Ltd’s market cap?
Zai Lab Ltd’s market cap is HK$17.16B.
When is Zai Lab Ltd’s upcoming earnings report date?
Zai Lab Ltd’s upcoming earnings report date is Aug 10, 2026 which is in 81 days.
How were Zai Lab Ltd’s earnings last quarter?
Zai Lab Ltd released its earnings results on May 07, 2026. The company reported -HK$0.36 earnings per share for the quarter, beating the consensus estimate of -HK$0.416 by HK$0.056.
Is Zai Lab Ltd overvalued?
According to Wall Street analysts Zai Lab Ltd’s price is currently Undervalued.
Does Zai Lab Ltd pay dividends?
Zai Lab Ltd does not currently pay dividends.
What is Zai Lab Ltd’s EPS estimate?
Zai Lab Ltd’s EPS estimate is -0.53.
How many shares outstanding does Zai Lab Ltd have?
Zai Lab Ltd has 1,134,128,000 shares outstanding.
What happened to Zai Lab Ltd’s price movement after its last earnings report?
Zai Lab Ltd reported an EPS of -HK$0.36 in its last earnings report, beating expectations of -HK$0.416. Following the earnings report the stock price went up 0.124%.
Which hedge fund is a major shareholder of Zai Lab Ltd?
Currently, no hedge funds are holding shares in HK:9688
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Zai Lab Ltd Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
HK$27.93 (52.88% Upside)
HK$27.93 (52.88% Upside)
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Fundamentals
Return on Equity
-24.29%
Trailing 12-Months
Asset Growth
-12.45%
Trailing 12-Months
Company Description
Zai Lab Ltd
Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience primarily in Mainland China and Hong Kong. The company's commercial products include Zejula, a once-daily small-molecule poly polymerase 1/2 inhibitor; Optune, a device that delivers tumor treating fields; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; and Qinlock to treat gastrointestinal stromal tumors. It also develops Odronextamab to treat follicular lymphoma, diffuse large B-cell lymphoma, and other B-celllymphomas; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer patients; Margetuximab for the treatment of breast and gastroesophageal cancers; Adagrasib for treating KRAS-G12C-mutated NSCLC, colorectal cancer, pancreatic cancer, and other solid tumors; and Bemarituzumab to treat gastric and gastroesophageal junction cancer. In addition, the company develops CLN-081 for the treatment of patients with EGFR exon 20 insertion NSCLC; Elzovantinib, an orally bioavailable multi-targeted kinase inhibitor; Tebotelimab, a tetravalent IgG4 monoclonal antibody; Retifanlimab that inhibits interactions between PD-1 and its ligands; ZL-2309, an orally active, selective, and ATP-competitive cell division cycle 7 (CDC7) kinase inhibitor; ZL-1201, a humanized IgG4 monoclonal antibody; Efgartigimod to reduce disease-causing immunoglobulin G antibodies; ZL-1102, a human nanobody targeting interleukin- 17A; KarXT for the treatment of psychiatric and neurological conditions; ZL-2313, an investigational inhibitor of triple-mutant EGFR harboring; ZL-2314, an investigational inhibitor of double-mutant EGFR harboring; and Sulbactam/durlobactam for the treatment of serious infections caused by Acinetobacter. Zai Lab Limited was incorporated in 2013 and is headquartered in Shanghai, China.
9688 Stock 12 Month Forecast
Average Price Target
HK$27.93
▲(52.88% Upside)
Technical Analysis
InnoCare Pharma Ltd.
―
Everest Medicines Ltd.
―
CARsgen Therapeutics Holdings Ltd.
―
CStone Pharmaceuticals
―
Ascentage Pharma Group International
―
Options Prices
Currently, No data available
---